Cargando…
Care pathways for people with major depressive disorder: A European Brain Council Value of Treatment study
BACKGROUND: Despite well-established guidelines for managing major depressive disorder, its extensive disability burden persists. This Value of Treatment mission from the European Brain Council aimed to elucidate the nature and extent of “gaps” between best-practice and current-practice care, specif...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280921/ https://www.ncbi.nlm.nih.gov/pubmed/35703080 http://dx.doi.org/10.1192/j.eurpsy.2022.28 |
_version_ | 1784746759287734272 |
---|---|
author | Strawbridge, Rebecca McCrone, Paul Ulrichsen, Andrea Zahn, Roland Eberhard, Jonas Wasserman, Danuta Brambilla, Paolo Schiena, Giandomenico Hegerl, Ulrich Balazs, Judit Caldas de Almeida, Jose Antunes, Ana Baltzis, Spyridon Carli, Vladmir Quoidbach, Vinciane Boyer, Patrice Young, Allan H. |
author_facet | Strawbridge, Rebecca McCrone, Paul Ulrichsen, Andrea Zahn, Roland Eberhard, Jonas Wasserman, Danuta Brambilla, Paolo Schiena, Giandomenico Hegerl, Ulrich Balazs, Judit Caldas de Almeida, Jose Antunes, Ana Baltzis, Spyridon Carli, Vladmir Quoidbach, Vinciane Boyer, Patrice Young, Allan H. |
author_sort | Strawbridge, Rebecca |
collection | PubMed |
description | BACKGROUND: Despite well-established guidelines for managing major depressive disorder, its extensive disability burden persists. This Value of Treatment mission from the European Brain Council aimed to elucidate the nature and extent of “gaps” between best-practice and current-practice care, specifically to: 1. Identify current treatment gaps along the care pathway and determine the extent of these gaps in comparison with the stepped-care model and 2. Recommend policies intending to better meet patient needs (i.e., minimize treatment gaps). METHODS: After agreement upon a set of relevant treatment gaps, data pertaining to each gap were gathered and synthesized from several sources across six European countries. Subsequently, a modified Delphi approach was undertaken to attain consensus among an expert panel on proposed recommendations for minimizing treatment gaps. RESULTS: Four recommendations were made to increase the depression diagnosis rate (from ~50% episodes), aiming to both increase the number of patients seeking help, and the likelihood of a practitioner to correctly detect depression. These should reduce time to treatment (from ~1 to ~8 years after illness onset) and increase rates of treatment; nine further recommendations aimed to increase rates of treatment (from ~25 to ~50% of patients currently treated), mainly focused on targeting the best treatment to each patient. To improve follow-up after treatment initiation (from ~30 to ~65% followed up within 3 months), seven recommendations focused on increasing continuity of care. For those not responding, 10 recommendations focused on ensuring access to more specialist care (currently at rates of ~5–25% of patients). CONCLUSIONS: The treatment gaps in depression care are substantial and concerning, from the proportion of people not entering care pathways to those stagnating in primary care with impairing and persistent illness. A wide range of recommendations can be made to enhance care throughout the pathway. |
format | Online Article Text |
id | pubmed-9280921 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-92809212022-07-29 Care pathways for people with major depressive disorder: A European Brain Council Value of Treatment study Strawbridge, Rebecca McCrone, Paul Ulrichsen, Andrea Zahn, Roland Eberhard, Jonas Wasserman, Danuta Brambilla, Paolo Schiena, Giandomenico Hegerl, Ulrich Balazs, Judit Caldas de Almeida, Jose Antunes, Ana Baltzis, Spyridon Carli, Vladmir Quoidbach, Vinciane Boyer, Patrice Young, Allan H. Eur Psychiatry Research Article BACKGROUND: Despite well-established guidelines for managing major depressive disorder, its extensive disability burden persists. This Value of Treatment mission from the European Brain Council aimed to elucidate the nature and extent of “gaps” between best-practice and current-practice care, specifically to: 1. Identify current treatment gaps along the care pathway and determine the extent of these gaps in comparison with the stepped-care model and 2. Recommend policies intending to better meet patient needs (i.e., minimize treatment gaps). METHODS: After agreement upon a set of relevant treatment gaps, data pertaining to each gap were gathered and synthesized from several sources across six European countries. Subsequently, a modified Delphi approach was undertaken to attain consensus among an expert panel on proposed recommendations for minimizing treatment gaps. RESULTS: Four recommendations were made to increase the depression diagnosis rate (from ~50% episodes), aiming to both increase the number of patients seeking help, and the likelihood of a practitioner to correctly detect depression. These should reduce time to treatment (from ~1 to ~8 years after illness onset) and increase rates of treatment; nine further recommendations aimed to increase rates of treatment (from ~25 to ~50% of patients currently treated), mainly focused on targeting the best treatment to each patient. To improve follow-up after treatment initiation (from ~30 to ~65% followed up within 3 months), seven recommendations focused on increasing continuity of care. For those not responding, 10 recommendations focused on ensuring access to more specialist care (currently at rates of ~5–25% of patients). CONCLUSIONS: The treatment gaps in depression care are substantial and concerning, from the proportion of people not entering care pathways to those stagnating in primary care with impairing and persistent illness. A wide range of recommendations can be made to enhance care throughout the pathway. Cambridge University Press 2022-06-15 /pmc/articles/PMC9280921/ /pubmed/35703080 http://dx.doi.org/10.1192/j.eurpsy.2022.28 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited. |
spellingShingle | Research Article Strawbridge, Rebecca McCrone, Paul Ulrichsen, Andrea Zahn, Roland Eberhard, Jonas Wasserman, Danuta Brambilla, Paolo Schiena, Giandomenico Hegerl, Ulrich Balazs, Judit Caldas de Almeida, Jose Antunes, Ana Baltzis, Spyridon Carli, Vladmir Quoidbach, Vinciane Boyer, Patrice Young, Allan H. Care pathways for people with major depressive disorder: A European Brain Council Value of Treatment study |
title | Care pathways for people with major depressive disorder: A European Brain Council Value of Treatment study |
title_full | Care pathways for people with major depressive disorder: A European Brain Council Value of Treatment study |
title_fullStr | Care pathways for people with major depressive disorder: A European Brain Council Value of Treatment study |
title_full_unstemmed | Care pathways for people with major depressive disorder: A European Brain Council Value of Treatment study |
title_short | Care pathways for people with major depressive disorder: A European Brain Council Value of Treatment study |
title_sort | care pathways for people with major depressive disorder: a european brain council value of treatment study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280921/ https://www.ncbi.nlm.nih.gov/pubmed/35703080 http://dx.doi.org/10.1192/j.eurpsy.2022.28 |
work_keys_str_mv | AT strawbridgerebecca carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy AT mccronepaul carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy AT ulrichsenandrea carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy AT zahnroland carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy AT eberhardjonas carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy AT wassermandanuta carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy AT brambillapaolo carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy AT schienagiandomenico carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy AT hegerlulrich carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy AT balazsjudit carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy AT caldasdealmeidajose carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy AT antunesana carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy AT baltzisspyridon carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy AT carlivladmir carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy AT quoidbachvinciane carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy AT boyerpatrice carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy AT youngallanh carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy |